Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIDIL vs ALBALON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Naphazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic amine, stimulating alpha-adrenergic receptors in the conjunctival arterioles, resulting in vasoconstriction and decreased congestion.
Allergic rhinitis,Allergic conjunctivitis,Urticaria,Angioedema
FDA-approved: Relief of redness and itching of the eye due to minor eye irritations (e.g., smoke, dust, wind, swimming, or wearing contact lenses).,Off-label: Treatment of allergic conjunctivitis symptoms (as an adjunct).
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
1-2 drops in affected eye(s) every 3-4 hours; frequency may be increased to every 2 hours in severe cases.
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life is 4-6 hours; clinically, dosing every 6-8 hours is recommended, with adjustments in renal impairment
Hepatic via CYP450 isoenzymes (primarily CYP3A4 and CYP2D6); undergoes N-demethylation and N-oxidation.
Primarily metabolized in the liver via oxidative deamination by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary/fecal elimination (10-15%)
Approximately 90% bound to plasma proteins, primarily albumin.
Approximately 99% bound to serum albumin and alpha-1-acid glycoprotein
2.5-4.0 L/kg, indicating extensive tissue distribution.
0.5-0.8 L/kg, indicating distribution into total body water with moderate tissue binding
Oral bioavailability is approximately 50-60% due to first-pass metabolism.
Oral: 60-70% due to first-pass metabolism; Ophthalmic: negligible systemic absorption (<1%)
GFR 10-50 m L/min: 2.5 mg every 6-8 hours; GFR <10 m L/min: 2.5 mg every 8-12 hours.
No dosage adjustment required; systemic absorption minimal.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
No dosage adjustment required; not studied in hepatic impairment.
Children 2-5 years: 1.25 mg orally every 4-6 hours (max 5 mg/day); Children 6-12 years: 1.25-2.5 mg every 4-6 hours (max 7.5 mg/day).
Children ≥3 years: same as adult dosing; children <3 years: safety and efficacy not established.
Initiate at 1.25 mg orally every 6-8 hours; maximum 5 mg per day due to increased risk of anticholinergic effects and renal impairment.
No specific adjustment; use with caution due to possible increased sensitivity to anticholinergic effects.
None
No FDA black box warning.
May cause drowsiness and impair mental alertness,Avoid alcohol and other CNS depressants,Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, or urinary retention,Elderly patients are more susceptible to anticholinergic effects
Use with caution in patients with cardiovascular disease (e.g., hypertension, arrhythmias) or hyperthyroidism due to systemic absorption.,Prolonged use may lead to rebound congestion (rhinitis medicamentosa) if used intranasally; ocular overuse may cause reactive hyperemia.,Avoid in patients with narrow-angle glaucoma (risk of angle closure).,Monitor for systemic effects (e.g., dizziness, headache, palpitations).
Hypersensitivity to any component,Concurrent use with monoamine oxidase inhibitors
Hypersensitivity to naphazoline or any component of the formulation.,Narrow-angle glaucoma (absolute contraindication).,Patients with severe cardiovascular disease (e.g., uncontrolled hypertension, coronary insufficiency).,Concomitant use with MAO inhibitors or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis).
No specific food interactions, but taking with food may reduce GI side effects. Alcohol should be strictly avoided due to additive CNS depression. Grapefruit juice is not documented to interact.
No specific food interactions; however, avoid alcohol as it may exacerbate ocular irritation or dizziness.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergic effects may cause neonatal tachycardia, irritability, and withdrawal symptoms if used near term.
AUX: Category C. Naphazoline is an imidazoline sympathomimetic with potential for vasoconstriction; systemic absorption may reduce uterine blood flow. First trimester: limited human data; animal studies not evaluated for malformations. Second/third trimester: possible fetal hypoxia due to vasoconstriction; avoid use near term due to risk of neonatal tachycardia, hypertension, and irritability.
Excretion into breast milk likely but negligible amounts; no adverse effects reported in infants. M/P ratio not established. Considered compatible with breastfeeding; monitor for sedation or irritability in neonate.
No human data on excretion in breast milk. M/P ratio unknown. Naphazoline likely passes into milk due to low molecular weight; risk of infant vasoconstrictive effects if absorbed. Use with caution; avoid prolonged or high-dose use while breastfeeding.
No specific dose adjustments required in pregnancy; however, use lowest effective dose due to potential anticholinergic effects. Pharmacokinetics may be altered (increased volume of distribution), but no dose adjustment recommended.
No dose adjustment recommended for topical ophthalmic use. Systemic absorption is negligible; however, if systemic effects occur, reduce frequency. Pregnancy may alter ocular pharmacokinetics, but no specific adjustment data available.
ACTIDIL (triprolidine) is a first-generation antihistamine with sedative properties. Use cautiously in elderly due to risk of confusion, urinary retention, and falls. Avoid in patients with narrow-angle glaucoma, BPH, or asthma. Administer with food if GI upset occurs. Onset of action is 30-60 minutes; duration 4-6 hours.
ALBALON (naphazoline/pheniramine) ophthalmic solution: Use with caution in patients with cardiovascular disease or hypertension due to naphazoline's alpha-adrenergic effects; limit use to 3-4 days to avoid rebound conjunctival hyperemia; do not use in patients with narrow-angle glaucoma; remove contact lenses before instillation and wait 15 minutes before reinserting.
Do not drive or operate heavy machinery until you know how this medication affects you; it can cause drowsiness.,Avoid alcohol and other CNS depressants, as they may increase sedation.,Take exactly as prescribed; do not exceed recommended dose.,If you miss a dose, skip it; do not double the next dose.,Notify your doctor if you experience blurred vision, difficulty urinating, or severe drowsiness.,Do not use for prolonged periods without medical advice.
Do not use while wearing soft contact lenses; remove lenses before using and wait at least 15 minutes before reinserting.,Avoid touching the dropper tip to any surface to prevent contamination.,Do not use more than 4 times daily or for longer than 72 hours without consulting a doctor; overuse can cause worsening redness.,Temporary stinging or blurred vision may occur upon instillation; do not drive until vision clears.,Seek medical attention if eye pain, vision changes, or persistent redness occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIDIL vs ALBALON, answered by our medical review team.
ACTIDIL is a Antihistamine that works by H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.. ALBALON is a Ophthalmic Antihistamine/Decongestant that works by Naphazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic amine, stimulating alpha-adrenergic receptors in the conjunctival arterioles, resulting in vasoconstriction and decreased congestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIDIL and ALBALON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIDIL is: 2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.. The standard adult dose of ALBALON is: 1-2 drops in affected eye(s) every 3-4 hours; frequency may be increased to every 2 hours in severe cases.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIDIL and ALBALON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIDIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Not associated with major congenital malformations. However, anticholinergi. ALBALON is classified as Category C. AUX: Category C. Naphazoline is an imidazoline sympathomimetic with potential for vasoconstriction; systemic absorption may reduce uterine blood flow. First trimester: limited huma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.